GelMEDIX Inc. is an early-stage biotechnology company leveraging its hydrogel platform to develop ocular and regenerative therapies that can restore vision.
GelMEDIX was founded after multiple years of fruitful academic collaboration between our co-founders Reza Dana (Mass. Eye And Ear, Harvard Med. School) and Nasim Annabi (UCLA).
Our proprietary photo-crosslinked hydrogels uniquely enable
bioadhesion, tissue regeneration, tunable mechanics, and therapeutic loading across modalities from small molecules to cell and gene therapies.
Our lead program is an integrated hydrogel cell therapy designed to
restore vision for macular degeneration patients with Dry AMD and GA.
Company Details
- Employees
- 12
- Founded
- 2020
- Address
- Labcentral, Cambridge,ma 02139,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.gelmedix.com
- HQ
- Cambridge, MA
Gelmedix Questions
Gelmedix's website is http://www.gelmedix.com
Gelmedix's LinkedIn profile is https://www.linkedin.com/company/gelmedix
Gelmedix has
12 employees.
View email and phone details for 12
employees at Gelmedix.
Gelmedix's industry is
Biotechnology Research
Gelmedix's top competitors are
Gensaic,
Cerberus Therapeutics,
Immunome, Inc.,
Ingel Therapeutics, Inc.,
Stalicla,
Dacapo Brainscience,
Frontera Therapeutics,
Inndura Therapeutics,
Eci Therapeutics,
Stratagen Bio.
Gelmedix's categories are Biotechnology Research
Gelmedix's founding year is 2020
